Literature DB >> 7434289

Sputum and blood concentrations of cefuroxime in lower respiratory tract infection.

C W Havard, R P Bax, T C Samanta, R M Pearson, W Brumfitt, J M Hamilton-Miller, C H Dash.   

Abstract

A detailed pharmacokinetic study of cefuroxime has been carried out. Levels of cefuroxime were determined in the blood, sputum, saliva, and urine of 23 patients receiving parenteral cefuroxime eight hourly for chest infections. Profiles were obtained after the first dose and on the final (fifth) day of treatment. Antibiotic levels in the sputum reached 0.8 mg/l within one hour of the first injection, and were maintained close to this value for six hours. There was a build-up by the fifth day, mean cefuroxime concentrations at this time reaching 1.8 mg/l. This concentration was maintained for a prolonged period. Salivary concentrations were detectable but low (maximum mean value was 0.6 mg/l). Concentrations of antibiotic were significantly higher in the serum than those observed after the same doses in volunteers. In the patients there was no build-up in serum levels between the first and fifth days. The data obtained explain the clinical efficacy of cefuroxime in the treatment of lower respiratory infections, and suggest that a 12-hour schedule may be feasible.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7434289      PMCID: PMC471295          DOI: 10.1136/thx.35.5.379

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  5 in total

1.  Microbiological studies on a new broad-spectrum penicilin, "Penbritin".

Authors:  G N ROLINSON; S STEVENS
Journal:  Br Med J       Date:  1961-07-22

2.  Cefuroxime: human pharmacokinetics..

Authors:  R D Foord
Journal:  Antimicrob Agents Chemother       Date:  1976-05       Impact factor: 5.191

3.  Cefuroxime - a new cephalosporin antibiotic.

Authors:  C H O'Callaghan; R B Sykes; D M Ryan; R D Foord; P W Muggleton
Journal:  J Antibiot (Tokyo)       Date:  1976-01       Impact factor: 2.649

4.  Determination of plasma and renal clearance of cefuroxime and its pharmacokinetics in renal insufficiency.

Authors:  R van Dalen; T B Vree; J C Hafkenscheid; J S Gimbrère
Journal:  J Antimicrob Chemother       Date:  1979-05       Impact factor: 5.790

5.  Cefuroxime: antimicrobial activity, human pharmacokinetics and therapeutic efficacy.

Authors:  G K Daikos; J C Kosmidis; C Stathakis; H Giamarellou
Journal:  J Antimicrob Chemother       Date:  1977-11       Impact factor: 5.790

  5 in total
  6 in total

Review 1.  Pharmacokinetics and tissue concentrations of cefuroxime.

Authors:  T B Vree; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1990-12-14

Review 2.  New drugs in respiratory disorders: II.

Authors:  D C Flenley
Journal:  Br Med J (Clin Res Ed)       Date:  1983-03-19

Review 3.  Recent advances in respiratory medicine.

Authors:  D C Flenley
Journal:  Postgrad Med J       Date:  1983-01       Impact factor: 2.401

4.  Cefuroxime axetil in acute purulent exacerbations of chronic bronchitis.

Authors:  B I Davies; F P Maesen; J P Teengs
Journal:  Infection       Date:  1987 Jul-Aug       Impact factor: 3.553

5.  Effectiveness of cephalosporins in the sputum of patients with nosocomial bronchopneumonia.

Authors:  Almos Klekner; Kinga Bagyi; Laszlo Bognar; Attila Gaspar; Melinda Andrasi; Judit Szabo
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

Review 6.  A Qualitative Review on the Pharmacokinetics of Antibiotics in Saliva: Implications on Clinical Pharmacokinetic Monitoring in Humans.

Authors:  Tony K L Kiang; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.